REG - RIT Cap. Partners - March Net Asset Value and Q1 2023 Commentary

RIT Capital PartnersAnnouncement

19/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230419:nRSS6551Wa&default-theme=true

RNS Number : 6551W  RIT Capital Partners PLC  19 April 2023

RIT CAPITAL PARTNERS PLC (LEI: P31Q1NLTW35JJGHA4667)

19 April 2023

 

31 March 2023 Net Asset Value

The unaudited diluted net asset value (NAV) of RIT Capital Partners plc as at
31 March 2023 (with debt at fair value) was 2,405p per £1 ordinary share (28
February 2023: 2,432p).

Q1 2023 Commentary

Turbulence continued during Q1, with markets gyrating between positive and
negative sentiment.  The early part of the quarter saw equities buoyed by
perceived lower recession risks and China's continued reopening, before a
combination of stronger economic and inflation data (raising the probability
of higher interest rates), coupled with the collapse of Credit Suisse and US
regional banks, raised concerns of a financial crisis and global recession.
Nonetheless global equity markets ended surprisingly strongly, lifted by a
small number of mega-cap tech companies viewed as more resilient to credit
tightening and a growth slowdown.

RIT's NAV total return for Q1 2023 was +0.7%.  Notwithstanding the increase
in RIT's NAV, the share price suffered from some negative sentiment.  We
continued to take advantage of this, buying back RIT shares accretively in
larger quantities than in previous years.

One area of recent discussion has been in relation to the robustness of the
valuation of RIT's private investments.  Our direct investments (representing
11.7% of NAV), are all held at audited 31 December fair values.  Subsequent
to the year end, we completed the sale of a core position (Infinity) in
January at a ~30% uplift to the carrying value (in line with our historical
average uplift).  One of our top 5 holdings (Webull) is completing an equity
issuance at a price above our carrying value, and we have agreed terms for a
sale from two other top 10 holdings at carrying value.

In relation to private funds (27.9% of NAV), 80% of these are now held at 31
December fair values from external managers (GPs).  Reinforcing the widely
diversified nature of the portfolio, these funds saw a blend of increases and
decreases, with a modest overall decline contributing -1.0% to NAV.  The
strong Q1 performance seen across major indices, including for long-duration
assets and fast-growing businesses, bodes well for valuations here in the
future.

We continued to hold our net quoted equity exposure towards the lower end of
our historical range, at 37% during Q1.  Overall, these assets contributed
+2.1% to NAV, with notable outperformance from our core biotech holding as
well as Builders FirstSource, a stock which is the largest supplier of
building products in the US.

Outside of equities, many of our other asset classes performed well, with
positive contributions from our credit positions as well as gold and interest
rates.  Currencies detracted from the NAV performance, with the US dollar
weakening as interest rate expectations declined, and with sterling ending the
quarter as the best performing G10 currency.

Towards the end of 2022, we started a process of raising a meaningful amount
of liquidity in order to ensure we held dry powder for the dislocation-driven
opportunities we expect to see.  By the end of March, we held cash and
short-dated gilts of around £340 million, as well as undrawn borrowings of
£85 million.

Share buybacks commenced following the end of the closed period on 28
February, with 2.4 million shares acquired by 31 March, contributing 0.32% to
NAV per share in terms of accretion benefit.

Overall, while we remain cautious, there are signs that attractive
opportunities are emerging in the new investment landscape.  We continue to
retain our usual robust portfolio construction, with a balanced approach to
the portfolio and a diverse set of distinct drivers.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NAVUWONROSUSAAR